![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Molecular Pharmacology, Vol 5, 49-59, Copyright © 1969 by the American Society for Pharmacology and Experimental Therapeutics
1 The Wellcome Research Laboratories, Burroughs Wellcome & Co. (U. S. A.),
Inc., Tuckahoe, New York 10707
Dihydrofolate reductase has been isolated from cells of the rodent malarial organism Plasmodium berghei by separation from the host cells with saponin and extraction by rupture in a French pressure cell. The enzyme exhibits certain distinctive properties which clearly distinguish it from the dihydrofolate (H2-folate) reductase isolated from the host cells (mouse erythrocytes) and from H2-folate reductases obtained from other sources, as reported in the literature. The molecular weight determined by gel filtration (190,000 ± 10%) is 9-10-fold higher than reported for most other H2-folate reductases. This value was not significantly decreased when the enzyme was passed over Sephadex G-100 columns in the presence of KCl, urea + 2-mercaptoethanol, or the substrate, H2-folate. The plasmodial H2-folate reductase is unlike bacterial enzymes in its stimulation by high concentrations of KCl and urea, and its approximately 10-fold lower Km value for NADPH (1.3 µM).
The enzyme from P. berghei differs markedly from other dihydrofolate reductases in its sensitivity to several diaminoheterocyclic inhibitors. Most striking is the inhibition by pyrimethamine; it exhibits a 50% inhibitory concentration of approximately 0.5 nM compared with 1 µM for the mouse erythrocyte enzyme. The binding of pyrimethamine to P. berghei dihydrofolate reductase is stoichiometric when enzyme and drug have been incubated for 5-10 min prior to the addition of H2-folate, and reversible in the absence of prior incubation. A positive correlation was observed between the binding of pyrimethamine and three dihydrotriazines by the enzyme and the activity of these compounds in vivo against P. berghei infections. These data establish that the selective action of pyrimethamine in malaria is due to the greater sensitivity to this drug of the plasmodial enzyme as compared to the host enzyme and reflect the unique, potent binding of pyrimethamine to plasmodial H2-folate reductase.
Submitted on September 9, 1968
This article has been cited by other articles:
|
|
 |
|
  A. AULIFF, D. W. WILSON, B. RUSSELL, Q. GAO, N. CHEN, L. N. ANH, J. MAGUIRE, D. BELL, M. T. O'NEIL, and Q. CHENG AMINO ACID MUTATIONS IN PLASMODIUM VIVAX DHFR AND DHPS FROM SEVERAL GEOGRAPHICAL REGIONS AND SUSCEPTIBILITY TO ANTIFOLATE DRUGS. Am J Trop Med Hyg, October 1, 2006; 75(4): 617 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. BURNS, J. BAKER, A. M. AULIFF, M. L. GATTON, M. D. EDSTEIN, and Q. CHENG EFFICACY OF SULFADOXINE-PYRIMETHAMINE IN THE TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA IN EAST TIMOR. Am J Trop Med Hyg, March 1, 2006; 74(3): 361 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Musset, B. Pradines, D. Parzy, R. Durand, P. Bigot, and J. Le Bras Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers J. Antimicrob. Chemother., January 1, 2006; 57(1): 110 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gregson and C. V. Plowe Mechanisms of Resistance of Malaria Parasites to Antifolates Pharmacol. Rev., March 1, 2005; 57(1): 117 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Zhang and P. K. Rathod Divergent Regulation of Dihydrofolate Reductase Between Malaria Parasite and Human Host Science, April 19, 2002; 296(5567): 545 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Patankar, A. Munasinghe, A. Shoaibi, L. M. Cummings, and D. F. Wirth Serial Analysis of Gene Expression in Plasmodium falciparum Reveals the Global Expression Profile of Erythrocytic Stages and the Presence of Anti-Sense Transcripts in the Malarial Parasite Mol. Biol. Cell, October 1, 2001; 12(10): 3114 - 3125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Fidock, T. Nomura, and T. E. Wellems Cycloguanil and Its Parent Compound Proguanil Demonstrate Distinct Activities against Plasmodium falciparum Malaria Parasites Transformed with Human Dihydrofolate Reductase Mol. Pharmacol., December 1, 1998; 54(6): 1140 - 1147. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
